Virtual reality for the treatment of posttraumatic disorders

Thiago Mazzoli Moraes¹
Almir Ferreira de Andrade²
Wellingson Silva Paiva²,³

¹Division of Psychology, ²Division of Neurosurgery, University of São Paulo Medical School, São Paulo, SP, Brazil; ³Neurology Center, Samaritano Hospital, São Paulo, SP, Brazil

Dear editor

We read with great interest the recent study by Botella et al¹ published in the journal Neuropsychiatric Disease and Treatment. Virtual reality (VR) technology has allowed for the neuropsychological rehabilitation in patients with many neurological diseases including stroke and traumatic brain injury.²,³ This contribution is due to the VR’s ability to create standardized environments (replicable and ecological) that are difficult to deliver and control in the real world.⁴,⁵ For example, exercises that would be too dangerous to be performed and practiced in the real world could be done in a virtual environment. The implementation of VR systems could allow the involvement of specialists and caregivers to easily modify the tasks according to the needs and difficulties of the patient.⁶ Botella et al’s¹ paper focused on reviewing the use of virtual reality exposure-based therapy (VR-EBT) and its adequacy, acceptability, and efficacy in the treatment of patients with posttraumatic stress disorder.

Botella et al¹ performed a broad review about the use of VR-EBT, discussing the recommended duration, periodicity, and number of sessions. This way, the authors showed a relative lack of standardization among the articles reviewed, making the comparison of results difficult. However, the recommended session duration proposed by the authors (90 minutes) should be interpreted with caution. Exposure to VR can lead to symptoms of cybersickness, for example, eye strain, headache, sweating, nausea, and disorientation.⁶ These symptoms can be enhanced by the type of technology used and the amount of time the person was exposed to it. In this review by Botella et al¹, most articles used a head-mounted display (nine out of 12) as the VR device. Head-mounted displays have been reported to cause increased levels of nausea compared with desktop viewing.⁷ This effect can be diminished with the use of a head-tracking system, higher quality devices, and devices with lower latency.⁶

Despite the exhaustive discussion of treatments in this paper, some considerations were not included; the type of VR device and the quality of the virtual environment may have influenced the results obtained and if the gain achieved by the treatment with virtual reality justify the increased cost. Finally, they failed to consider an aspect that we believe is important in clinical use of VR system: the importance of the therapist involvement in the treatment outcome. So, as described by Botella et al¹, VR-EBT in the treatment of neuropsychiatric diseases is a promising method. These small caveats, however, do not take away the main relevant messages and discussion raised by Botella et al¹.

Correspondence: Wellingson Silva Paiva
Division of Neurosurgery, University of São Paulo Medical School, Alves Guimarães Street 470, 05410000 São Paulo, SP, Brazil
Tel +55 11 2548 6900
Fax +55 11 2548 6906
Email wellingsonpaiva@yahoo.com.br

© 2016 Moraes et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Disclosure
The authors report no conflicts of interest in this communication.

References

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.